- Home
- NXTC vs ARKR Comparison
NXTC vs ARKR Comparison
Compare NXTC & ARKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- ARKR
- Stock Information
- Founded
- NXTC 2015
- ARKR 1983
- Country
- NXTC United States
- ARKR United States
- Employees
- NXTC N/A
- ARKR N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- ARKR Restaurants
- Sector
- NXTC Health Care
- ARKR Consumer Discretionary
- Exchange
- NXTC Nasdaq
- ARKR Nasdaq
- Market Cap
- NXTC 40.3M
- ARKR 48.2M
- IPO Year
- NXTC 2019
- ARKR N/A
- Fundamental
- Price
- NXTC $1.42
- ARKR $11.59
- Analyst Decision
- NXTC Strong Buy
- ARKR
- Analyst Count
- NXTC 2
- ARKR 0
- Target Price
- NXTC $6.00
- ARKR N/A
- AVG Volume (30 Days)
- NXTC 23.4K
- ARKR 5.4K
- Earning Date
- NXTC 10-31-2024
- ARKR 08-12-2024
- Dividend Yield
- NXTC N/A
- ARKR 6.47%
- EPS Growth
- NXTC N/A
- ARKR N/A
- EPS
- NXTC N/A
- ARKR N/A
- Revenue
- NXTC N/A
- ARKR $184,539,000.00
- Revenue This Year
- NXTC N/A
- ARKR N/A
- Revenue Next Year
- NXTC N/A
- ARKR N/A
- P/E Ratio
- NXTC N/A
- ARKR N/A
- Revenue Growth
- NXTC N/A
- ARKR N/A
- 52 Week Low
- NXTC $0.98
- ARKR $10.27
- 52 Week High
- NXTC $2.57
- ARKR $16.27
- Technical
- Relative Strength Index (RSI)
- NXTC 34.28
- ARKR 38.38
- Support Level
- NXTC $1.41
- ARKR $11.45
- Resistance Level
- NXTC $1.65
- ARKR $12.96
- Average True Range (ATR)
- NXTC 0.09
- ARKR 0.45
- MACD
- NXTC -0.02
- ARKR -0.05
- Stochastic Oscillator
- NXTC 14.81
- ARKR 5.65
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.
About ARKR Ark Restaurants Corp.
Ark Restaurants Corp owns and operates around 17 restaurants and bars, 16 fast food concepts, and catering operations in the USA. The Las Vegas operations include New York Hotel & Casino Resort, hotel room service operations, banquet facilities, employee dining room, food court concepts, and a restaurant within the Planet Hollywood Resort and Casino. It operates a restaurant and a bar in the Resorts Atlantic City Hotel and Casino and a restaurant in the Tropicana Hotel and Casino. The Florida operations include The Rustic Inn in Dania Beach, Shuckers in Jensen Beach, JB's on the Beach in Deerfield Beach, The Blue Moon Fish Company in Fort Lauderdale, and fast food facilities in Tampa and Hollywood. In Alabama, it operates Original Oyster Houses in Gulf Shores and Spanish Fort.